

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

**POLL RESULTS OF THE ANNUAL GENERAL MEETING
HELD ON JUNE 10, 2022**

The board announces that at the AGM held on June 10, 2022, all proposed resolutions as set out in the notice of the AGM dated May 18, 2022 were duly passed by the relevant shareholders of the Company by way of poll.

The board (the “**Board**”) of directors (the “**Directors**”) of WuXi Biologics (Cayman) Inc. 藥明生物技術有限公司* (the “**Company**”) announces that at the annual general meeting of the Company (the “**AGM**”) held on June 10, 2022, all proposed resolutions as set out in the notice of the AGM dated May 18, 2022 were duly passed by the relevant shareholders of the Company by way of poll. Unless otherwise defined, terms used herein shall have the same meanings as those defined in the circular dated May 18, 2022 (the “**Circular**”). The executive Directors, Dr. Zhisheng Chen and Dr. Weichang Zhou; the non-executive Directors, Dr. Ge Li and Mr. Yibing Wu; and the independent non-executive Directors, Mr. William Robert Keller and Mr. Teh-Ming Walter Kwauk attended the AGM either in person or by electronic means.

The poll results taken at the AGM were as follows:

Ordinary Resolutions		Number of Votes (Approximate %)	
		For	Against
1.	To receive the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and of the independent auditor of the Company for the year ended December 31, 2021.	3,004,113,836 (99.73%)	7,998,932 (0.27%)
2.	(a) To re-elect Dr. Weichang Zhou as executive Director.	2,480,019,032 (82.42%)	528,833,410 (17.58%)
	(b) To re-elect Mr. Yibing Wu as non-executive Director.	2,051,107,729 (68.17%)	957,744,713 (31.83%)
	(c) To re-elect Mr. Yanling Cao as non-executive Director.	1,879,083,660 (62.45%)	1,129,768,782 (37.55%)
3.	To authorize the Board or any duly authorized board committee to fix the Directors' remuneration for the year ending December 31, 2022.	2,921,518,875 (97.03%)	89,441,393 (2.97%)
4.	To re-appoint Messrs. Deloitte Touche Tohmatsu as auditors and to authorize the Board or any duly authorized board committee to fix their remuneration.	2,976,893,369 (98.83%)	35,219,399 (1.17%)
5.	To grant a general mandate to the Directors to issue, allot and deal with the shares of the Company.	2,431,481,577 (80.72%)	580,631,191 (19.28%)
6.	To grant a general mandate to the Directors to repurchase the shares of the Company.	3,006,876,531 (99.83%)	5,236,237 (0.17%)
7.	To grant a specific mandate to the Directors to issue and allot the Connected Restricted Shares.	2,309,345,249 (76.67%)	702,767,519 (23.33%)
8.	To grant (a) 1,324,333 Connected Restricted Shares pursuant to the Scheme; and (b) 877,694 Connected Restricted Shares pursuant to the Program to Dr. Zhisheng Chen.	2,307,189,569 (76.60%)	704,866,535 (23.40%)
9.	To grant (a) 450,281 Connected Restricted Shares pursuant to the Scheme; and (b) 298,416 Connected Restricted Shares pursuant to the Program to Dr. Weichang Zhou.	2,307,189,569 (76.60%)	704,866,535 (23.40%)
10.	To grant 4,145 Connected Restricted Shares pursuant to the Scheme to Mr. William Robert Keller.	2,356,321,069 (78.23%)	655,735,035 (21.77%)
11.	To grant 4,145 Connected Restricted Shares pursuant to the Scheme to Mr. Teh-Ming Walter Kwauk.	2,356,321,069 (78.23%)	655,735,035 (21.77%)
12.	To grant 8,291 Connected Restricted Shares pursuant to the Scheme to Mr. Kenneth Walton Hitchner III.	2,356,321,069 (78.23%)	655,735,035 (21.77%)

Ordinary Resolutions		Number of Votes (Approximate %)	
		For	Against
13.	To grant (a) 33,565 Connected Restricted Shares pursuant to the Scheme; and (b) 29,251 Connected Restricted Shares pursuant to the Program to Mr. Angus Scott Marshall Turner.	2,307,246,233 (76.60%)	704,866,535 (23.40%)
14.	To grant (a) 12,424 Connected Restricted Shares pursuant to the Scheme; and (b) 17,786 Connected Restricted Shares pursuant to the Program to Mr. Brendan McGrath.	2,307,246,233 (76.60%)	704,866,535 (23.40%)
15.	To grant 32,160,000 share options pursuant to the share option scheme of WuXi XDC Cayman Inc. adopted by shareholders of the Company on November 23, 2021 to Dr. Jincai Li.	2,169,041,082 (72.08%)	840,293,686 (27.92%)
16.	To grant 31,980,000 share options pursuant to the share option scheme of WuXi Vaccines (Cayman) Inc. adopted by shareholders of the Company on November 23, 2021 to Mr. Jian Dong.	2,169,041,082 (72.08%)	840,293,686 (27.92%)
Special Resolution		Number of Votes (Approximate %)	
		For	Against
17.	To approve the adoption of the second amended and restated memorandum and articles of association of the Company, which contain the proposed amendments to the existing Memorandum and Articles of Association of the Company as set out in Appendix III of the circular of the Company dated May 18, 2022, in substitution for and to the exclusion of the existing Memorandum and Articles of Association.	2,916,135,620 (96.81%)	95,977,148 (3.19%)

As at the date of the AGM, the total number of shares of the Company in issue, was 4,259,265,470 Shares.

As stated in the Circular, the respective Connected Grantees, Dr. Jincai Li and Mr. Jian Dong and their respective associates holding Shares were required to abstain and they had abstained from voting on the relevant resolutions numbered 7 to 16 in respect of the grant of Specific Mandate and the grant of Connected Restricted Shares to Connected Grantees, the grant of WuXi XDC Share Options to Dr. Jincai Li and the grant of WuXi Vaccines Share Options to Mr. Jian Dong proposed at the AGM.

To the best knowledge and belief of the Company, after making all reasonable enquiries, as at the date of the AGM, (i) Dr. Zhisheng Chen and his associates hold 12,252,988 Shares; (ii) Dr. Weichang Zhou and his associates hold 47,754 Shares; (iii) Mr. William Robert Keller and his associates hold 15,307 Shares; (iv) Mr. Teh-Ming Walter Kwauk and his associates hold 13,675 Shares; (v) Mr. Kenneth Walton Hitchner III and his associates hold 40,000 Shares, (vi) Dr. Jincal Li and his associates hold 365,027 Shares, and (vii) Mr. Jian Dong and his associates hold 1,841,890 Shares. Mr. Angus Scott Marshall Turner and Mr. Brendan McGrath and their respective associates do not hold any Shares.

Accordingly, as at the date of the AGM, the respective total number of Shares entitling the holders to attend and vote on resolutions numbered 1 to 6 and 17 were 4,259,265,470 Shares, being the total number of issued Shares as at the date of the AGM, and on resolutions numbered 7 to 16 were 4,246,895,746 Shares, 4,247,012,482 Shares, 4,259,217,716 Shares, 4,259,250,163 Shares, 4,259,251,795 Shares, 4,259,225,470 Shares, 4,259,265,470 Shares, 4,259,265,470 Shares, 4,258,900,443 Shares, and 4,257,423,580 Shares, respectively.

Save as disclosed above, there were no restrictions on any shareholders of the Company to cast votes on any of the resolutions proposed at the AGM. No shareholder of the Company has stated his/her/its intention in the Company's Circular to vote against or to abstain from voting on any of the resolutions at the AGM.

The Company's Hong Kong branch share registrar, Tricor Investor Services Limited, was appointed as the scrutineer for the vote-taking at the AGM.

For and on behalf of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, June 10, 2022

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Dr. Ning Zhao, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Kenneth Walton Hitchner III as independent non-executive Directors.

* *For identification purpose only*